Your browser doesn't support javascript.
loading
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
Tweehuysen, Lieke; van den Bemt, Bart J F; van Ingen, Iris L; de Jong, Alphons J L; van der Laan, Willemijn H; van den Hoogen, Frank H J; den Broeder, Alfons A.
Afiliação
  • Tweehuysen L; Sint Maartenskliniek, Nijmegen, The Netherlands.
  • van den Bemt BJF; Sint Maartenskliniek and Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Ingen IL; Radboud University Medical Center, Nijmegen, The Netherlands.
  • de Jong AJL; Rijnstate, Arnhem, The Netherlands.
  • van der Laan WH; Maartenskliniek, Woerden, The Netherlands.
  • van den Hoogen FHJ; Sint Maartenskliniek and Radboud University Medical Center, Nijmegen, The Netherlands.
  • den Broeder AA; Sint Maartenskliniek and Radboud University Medical Center, Nijmegen, The Netherlands.
Arthritis Rheumatol ; 70(1): 60-68, 2018 01.
Article em En | MEDLINE | ID: mdl-29045077

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite / Antirreumáticos / Medicamentos Biossimilares / Infliximab / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite / Antirreumáticos / Medicamentos Biossimilares / Infliximab / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda